Video

Dr. Campbell on the Future of the Management of RCC

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the future of the treatment management for patients with renal cell carcinoma (RCC).

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the future of the treatment management for patients with renal cell carcinoma (RCC).

In the future, researchers hope to see an increased utilization of partial nephrectomy and a more sensible utilization of radical nephrectomy, states Campbell.

Many are advocating for a utility-based approach to renal mass biopsy, meaning it will only be applied to patients who might have their treatment management changed, explains Campbell.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD